




Edition: BP 2025 (Ph. Eur. 11.6 update)

# Aceclofenac

[General Notices](#)

(Ph. Eur. monograph 1281)



C<sub>16</sub>H<sub>13</sub>Cl<sub>2</sub>NO<sub>4</sub>    354.2    89796-99-6

**Action and use**

Cyclo-oxygenase inhibitor; analgesic; anti-inflammatory.

Ph Eur

## DEFINITION

[[[2-[(2,6-Dichlorophenyl)amino]phenyl]acetyl]oxy]acetic acid.

**Content**

99.0 per cent to 101.0 per cent (dried substance).

## CHARACTERS

**Appearance**

White or almost white, crystalline powder.

**Solubility**

Practically insoluble in water, freely soluble in acetone, soluble in ethanol (96 per cent).

## IDENTIFICATION

First identification: B.

Second identification: A, C.

A. Ultraviolet and visible absorption spectrophotometry ([2.2.25](#)).

*Test solution* Dissolve 50.0 mg in [methanol R](#) and dilute to 100.0 mL with the same solvent. Dilute 2.0 mL of the solution to 50.0 mL with [methanol R](#).

*Spectral range* 220-370 nm.

*Absorption maximum* 275 nm.

*Specific absorbance at the absorption maximum* 320 to 350.

B. Infrared absorption spectrophotometry ([2.2.24](#)).

*Comparison:* [Ph. Eur. reference spectrum of aceclofenac](#).

C. Dissolve about 10 mg in 10 mL of [ethanol \(96 per cent\) R](#). To 1 mL of the solution, add 0.2 mL of a mixture, prepared immediately before use, of equal volumes of a 6 g/L solution of [potassium ferricyanide R](#) and a 9 g/L solution of [ferric chloride R](#). Allow to stand protected from light for 5 min. Add 3 mL of a 10.0 g/L solution of [hydrochloric acid R](#). Allow to stand protected from light for 15 min. A blue colour develops and a precipitate is formed.

## TESTS

### Related substances

Liquid chromatography ([2.2.29](#)). *Prepare the solutions immediately before use.*

*Solvent mixture* Mobile phase A, mobile phase B (30:70 V/V).

*Test solution* Dissolve 50.0 mg of the substance to be examined in the solvent mixture and dilute to 25.0 mL with the solvent mixture.

*Reference solution (a)* Dissolve 21.6 mg of [diclofenac sodium CRS](#) (impurity A) in the solvent mixture and dilute to 50.0 mL with the solvent mixture.

*Reference solution (b)* Dilute 2.0 mL of the test solution to 10.0 mL with the solvent mixture.

*Reference solution (c)* Mix 1.0 mL of reference solution (a) and 1.0 mL of reference solution (b) and dilute to 100.0 mL with the solvent mixture.

*Reference solution (d)* Dissolve 4.0 mg of [aceclofenac impurity F CRS](#) in the solvent mixture and dilute to 10.0 mL with the solvent mixture.

*Reference solution (e)* Dissolve 2.0 mg of [aceclofenac impurity H CRS](#) in the solvent mixture and dilute to 10.0 mL with the solvent mixture.

*Reference solution (f)* Mix 1.0 mL of reference solution (b), 1.0 mL of reference solution (d) and 1.0 mL of reference solution (e) and dilute to 100.0 mL with the solvent mixture.

*Reference solution (g)* Dissolve 5.0 mg of [aceclofenac impurity I CRS](#) in the solvent mixture and dilute to 50.0 mL with solvent mixture. Dilute 1.0 mL of the solution to 50.0 mL with the solvent mixture.

*Reference solution (h)* Dissolve 4 mg of [aceclofenac for peak identification CRS](#) (containing impurities B, C, D, E and G) in 2 mL of the solvent mixture.

*Column:*

— *size:*  $l = 0.25$  m,  $\varnothing = 4.6$  mm;

— *stationary phase:* spherical [end-capped octadecylsilyl silica gel for chromatography R](#) (5  $\mu$ m) with a pore size of 10 nm and a carbon loading of 19 per cent;

— *temperature:* 40 °C.

*Mobile phase:*

— *mobile phase A:* 1.12 g/L solution of [phosphoric acid R](#) adjusted to pH 7.0 with a 42 g/L solution of [sodium hydroxide R](#);

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 25	70 → 50	30 → 50
25 - 30	50 → 20	50 → 80
30 - 50	20	80

*Flow rate* 1.0 mL/min.

*Detection* Spectrophotometer at 275 nm.

*Injection* 10 µL of the test solution and reference solutions (c), (d), (e), (f), (g) and (h).

*Identification of impurities* Use the chromatogram obtained with reference solution (c) to identify the peak due to impurity A; use the chromatogram supplied with [aceclofenac for peak identification CRS](#) and the chromatogram obtained with reference solution (h) to identify the peaks due to impurities B, C, D, E and G; use the chromatogram obtained with reference solution (d) to identify the peak due to impurity F; use the chromatogram obtained with reference solution (e) to identify the peak due to impurity H; use the chromatogram obtained with reference solution (g) to identify the peak due to impurity I.

*Relative retention* With reference to aceclofenac (retention time = about 11 min): impurity A = about 0.8; impurity G = about 1.3; impurity H = about 1.5; impurity I = about 2.3; impurity D = about 3.1; impurity B = about 3.2; impurity E = about 3.3; impurity C = about 3.5; impurity F = about 3.7.

*System suitability* Reference solution (c):

— [resolution](#): minimum 5.0 between the peaks due to impurity A and aceclofenac.

*Limits:*

— *impurity A*: not more than the area of the corresponding peak in the chromatogram obtained with reference solution (c) (0.2 per cent);

— *impurities B, C, D, E, G*: for each impurity, not more than the area of the peak due to aceclofenac in the chromatogram obtained with reference solution (f) (0.2 per cent);

— *impurity F*: not more than the area of the corresponding peak in the chromatogram obtained with reference solution (f) (0.2 per cent);

— *impurity H*: not more than 1.5 times the area of the corresponding peak in the chromatogram obtained with reference solution (f) (0.15 per cent);

— *impurity I*: not more than 1.5 times the area of the corresponding peak in the chromatogram obtained with reference solution (g) (0.15 per cent);

— *unspecified impurities*: for each impurity, not more than 0.5 times the area of the peak due to aceclofenac in the chromatogram obtained with reference solution (f) (0.10 per cent);

— *total*: maximum 0.7 per cent;

— *disregard limit*: 0.25 times the area of the peak due to aceclofenac in the chromatogram obtained with reference solution (f) (0.05 per cent).

### [Loss on drying \(2.2.32\)](#)

Maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C.

### [Sulfated ash \(2.4.14\)](#)

Maximum 0.1 per cent, determined on 1.0 g.

## ASSAY

Dissolve 0.300 g in 40 mL of [methanol R](#). Titrate with [0.1 M sodium hydroxide](#), determining the end-point potentiometrically ([2.2.20](#)).


1 mL of [0.1 M sodium hydroxide](#) is equivalent to 35.42 mg of  $C_{16}H_{13}Cl_2NO_4$ .

## STORAGE


Protected from light.

## IMPURITIES


*Specified impurities* A, B, C, D, E, F, G, H, I.




A. [2-[(2,6-dichlorophenyl)amino]phenyl]acetic acid (diclofenac),




B. methyl [2-[(2,6-dichlorophenyl)amino]phenyl]acetate (methyl ester of diclofenac),




C. ethyl [2-[(2,6-dichlorophenyl)amino]phenyl]acetate (ethyl ester of diclofenac),




D. methyl [[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate (methyl ester of aceclofenac),




E. ethyl [[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate (ethyl ester of aceclofenac),




F. benzyl [[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate (benzyl ester of aceclofenac),



G. [[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetyl]oxy]acetic acid (acetic aceclofenac),



H. [[[[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetyl]oxy]acetyl]oxy]acetic acid (diacetic aceclofenac),



I. 1-(2,6-dichlorophenyl)-1,3-dihydro-2*H*-indol-2-one.